Chronic News and Research

RSS

Lack of exercise causes physical and psychological setbacks

Use it or lose it, fitness experts tell us. Now a new study offers evidence that the adage really does ring true – that a lack of exercise can not only cause physical setbacks, but also psychological setbacks as well.

16 Apr 2004

GlaxoSmithKline files asthma treatment drug for approval in Japan

GlaxoSmithKline plc announced today that it has filed SeretideTM DiskusTM for approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of asthma in adults and children.

16 Apr 2004

Bad hygiene may be good for you

A group of scientists at The Scripps Research Institute have found a connection between poor T cell survival in the body and the development of autoimmunity.

16 Apr 2004

Women get better picture on hormone replacement therapy

Detailed results of the "estrogen-alone" study within the Women's Health Initiative (WHI), which was terminated in early March 2004, are providing some of the first answers to questions about the efficacy of estrogen alone to prevent chronic disease in healthy, postmenopausal women who have had a hysterectomy.

14 Apr 2004

Protecting against West Nile virus

What's that buzzing noise? Believe it or not, mosquito season is already here again. Why do we even need mosquitoes? What purpose do these pesky insects serve? In the grand scheme of biology, mosquitoes are an important food source for other insects and birds, and fish eat their larvae.

14 Apr 2004

Drug duo prevents life-threatening condition in children undergoing stem cell transplant

A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant

14 Apr 2004

Researchers examine community-based drinkers rather than abstinent alcoholics

Almost all knowledge about brain damage due to chronic alcohol consumption has been gathered from alcoholics, who have generally been studied toward the end of their institutionalized treatment program (several weeks after their last drink) or many months into abstinence.

13 Apr 2004

Estrogen-alone hormone therapy had no effect on coronary heart disease risk

A large, multi-center heart disease prevention study, part of the Women's Health Initiative (WHI), found that estrogen-alone hormone therapy had no effect on coronary heart disease risk but increased the risk of stroke for postmenopausal women.

13 Apr 2004

Antimicrobial alginate dressing protects the wound with silver

Johnson & Johnson Wound Management today announced the introduction of SILVERCEL™ antimicrobial alginate dressing, providing the protection of silver and the absorption of alginate.

13 Apr 2004

Researchers have developed a new method for finding antigens

Researchers at National Jewish Medical and Research Center have developed a method for finding the molecular targets of the immune system, known as antigens.

13 Apr 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004

More doctors, better care, faster access

A report produced today by Primary Care National Director, Dr David Colin-Thome, shows that NHS primary care, the local healthcare people access most frequently, is continuing to expand and provide a wider range of services to patients.

13 Apr 2004

Vitamin C can reduce levels of C-reactive protein, a marker of inflammation and chronic disease

Vitamin C supplements can reduce levels of C-reactive protein, a marker of inflammation and chronic disease risk in humans, according to a new study led by researchers at the University of California, Berkeley.

12 Apr 2004

Green tea helps kill cells of the most common leukemia

Mayo Clinic researchers have discovered that a component in green tea helps kill cells of the most common leukemia in the United States.

12 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

Britain's NHS to buy large volume of mobile MRI scanners

British Health Secretary John Reid today invited bidders to supply the NHS with new, mobile, 'state of the art' MRI scanners and highly qualified staff to help cut waiting times across England. These new scanners will targeted at areas of greatest need. It's expected that they will be operational this summer.

8 Apr 2004

Cinacalet helps control overactive thyroids, a major complication of advanced kidney disease

A new drug can help control an overactive thyroid, a major complication of advanced kidney disease, by playing a trick on the gland, a new study finds. The drug, cinacalet, is much more effective at keeping the parathyroid gland working normally than a placebo, according to the study. It may be a good alternative to standard therapy, researchers said.

7 Apr 2004

Effects of lead in petrol are well-known however a recent additive to petrol manganese may be just as toxic

The disastrous environmental and health effects of lead in petrol are well-known, and western countries have been phasing it out for many years now. However, a recent additive to petrol - manganese - may be just as toxic. A Macquarie University study aims to find out.

7 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004

Michigan opens new center to treat exposure to Vermiculite, Taconite, Asbestos

In response to the United States Environmental Protection Agency's (EPA) identification of major sources of public asbestos exposure in Michigan, the Barbara Ann Karmanos Cancer Institute and the Center for Occupational and Environmental Medicine (COEM) affiliated with Wayne State University (WSU) have joined forces to establish The National Center for Vermiculite and Asbestos-Related Cancers.

5 Apr 2004